Brief: Obseva Announces Confirmation Of Positive CHMP Opinion For Linzagolix, An Oral Gnrh Antagonist, For Treatment Of Uterine Fibroids
25/04/2022 12:21
April 25 (Reuters) - Obseva SA OBSN.S :
* OBSEVA ANNOUNCES CONFIRMATION OF POSITIVE CHMP OPINION FOR
LINZAGOLIX, AN ORAL GNRH ANTAGONIST, FOR TREATMENT OF UTERINE
FIBROIDS
Source text for Eikon: ID:nGNX2Lc36B
Further company coverage: OBSN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary